Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells

International Journal of Oncology

Volumn 37, Issue 2, 2010, Pages 473-482

  Li, Zhuzhu ^a   Yao, Hangping ^b   Guin, Sunny ^a   Padhye, Snehal S ^a   Zhou, Yong Qing ^c   Wang, Ming Hai ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b State Key Laboratory for Diagnosis and Treatment of Infectious Diseases   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Epithelial cancer; Growth factor receptor; Mechanism of inhibition; Therapeutic antibody; Tumorigenic activities

Indexed keywords

BETA CATENIN; CONCANAMYCIN A; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; LACTACYSTIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ZTC9; MONOCLONAL ANTIBODY ZTF2; MONOCLONAL ANTIBODY ZTG4; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RON RECEPTOR TYROSINE KINASE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; RON PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEIN TRANSPORT; ANIMAL; ANTIBODY SPECIFICITY; CARCINOMA; COLON TUMOR; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; IMMUNOLOGY; MOUSE; OSMOLARITY; PATHOLOGY; PROTEIN PROCESSING; TUMOR CELL CULTURE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; CARCINOMA; COLONIC NEOPLASMS; DOWN-REGULATION; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; OSMOLAR CONCENTRATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN TRANSPORT; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR CELLS, CULTURED;

EID: 77954152767     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000696     Document Type: Article

References (49)

1. Zandi R, Larsen AB, Andersen P, Stockhausen MT and Poulsen HS: Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 19: 2013-2023, 2007. (Pubitemid 47353811)
2. Gao CF and Vande Woude GF: HGF/SF-Met signaling in tumor progression. Cell Res 15: 49-51, 2005.
3. Porter AC and Vaillancourt RR: Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis. Oncogene 17: 1343-1352, 1998.
4. Bache KG, Slagsvold T and Stenmark H: Defective down-regulation of receptor tyrosine kinases in cancer. EMBO J 23: 2707-2712, 2004. (Pubitemid 39013543)
5. Weinstein IB and Joe A: Oncogene addiction. Cancer Res 68: 3077-3080, 2008.
6. Fischgräbe J and Wülfing P: Targeted therapies in breast cancer: established drugs and recent developments. Curr Clin Pharmacol 3: 85-98, 2008.
7. Vincenzi B, Schiavon G, Silletta M, Santini D and Tonini G: The biological properties of cetuximab. Crit Rev Oncol Hematol 68: 93-106, 2008.
8. Shepard HM, Brdlik CM and Schreiber H: Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118: 3574-3581, 2008.
9. Tortora G, Ciardiello F and Gasparini G: Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Nat Clin Pract Oncol 5: 521-530, 2008.
10. Ronsin C, Muscatelli F, Mattei MG and Breathnach R: A novel putative receptor protein tyrosine kinase of the met family. Oncogene 8: 1195-1202, 1993. (Pubitemid 23129841)
11. Wang MH, Lee W, Luo YL, Weis MT and Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol 213: 402-411, 2007. (Pubitemid 350206512)
12. Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, Waltz SE and Lowy AM: The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res 67: 6075-6082, 2007. (Pubitemid 47037486)
13. Maggiora P, Marchio S, Stella MC, et al: Overexpression of the RON gene in human breast carcinoma. Oncogene 16: 2927-2933, 1998. (Pubitemid 28383277)
14. Lee WY, Chen HH, Chow NH, Su WC, Lin PW and Guo HR: Prognostic significance of co-expression of RON and MET receptors in node-negative breast cancer patients. Clin Cancer Res 11: 2222-2228, 2005.
15. Lee CT, Chow NH, Su PF, Lin SC, Lin PC and Lee JC: The prognostic significance of RON and MET receptor coexpression in patients with colorectal cancer. Dis Colon Rectum 51: 1268-1274, 2008.
16. Wang MH, Kurtz AL and Chen YQ: Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis 21: 1507-1512, 2000.
17. Collesi C, Santoro MM, Gaudino G and Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol 16: 5518-5526, 1996. (Pubitemid 26315071)
18. Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett 257: 157-164, 2007. (Pubitemid 47538834)
19. Peace BE, Toney-Earley K, Collins MH and Waltz SE: Ron receptor signaling augments mammary tumor formation and metastasis in a murine model of breast cancer. Cancer Res 65: 1285-1293, 2005. (Pubitemid 40270155)
20. Chen YQ, Zhou YQ, Fisher JH and Wang MH: Targeted expression of the receptor tyrosine kinase RON in distal lung epithelial cells results in multiple tumor formation: oncogenic potential of RON in vivo. Oncogene 21: 6382-6386, 2000.
21. Chan EL, Peace BE, Collins MH, Toney-Earley K and Waltz SE: Ron tyrosine kinase receptor regulates papilloma growth and malignant conversion in a murine model of skin carcinogenesis. Oncogene 24: 479-488, 2005. (Pubitemid 40188595)
22. Wagh PK, Peace BE and Waltz SE: Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res 100: 1-33, 2008. (Pubitemid 351942429)
23. Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol 12: 273-281, 2005. (Pubitemid 40616491)
24. Wang D, Shen Q, Chen YQ and Wang MH: Collaborative activities of macrophage-stimulating protein and transforming growth factor-beta1 in induction of epithelial to mesenchymal transition: roles of the RON receptor tyrosine kinase. Oncogene 23: 1668-1680, 2004.
25. Acloque H, Adams MS, Fishwick K, Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 119: 1438-1449, 2009.
26. Turley EA, Veiseh M, Radisky DC and Bissell MJ: Mechanisms of disease: epithelial-mesenchymal transition - does cellular plasticity fuel neoplastic progression? Nat Clin Pract Oncol 5: 280-290, 2008.
27. Wang MH, Yao HP and Zhou YQ: Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 27: 641-650, 2006.
28. Xu XM, Wang D, Shen Q, Chen YQ and Wang MH: RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells. Oncogene 23: 8464-8474, 2004.
29. Wang J, Rajput A, Kan JL, et al: Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 284: 10912-10922, 2009.
30. Wang MH, Lao WF, Wang D, Luo YL and Yao HP: Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain. Cancer Biol Ther 6: 1121-1129, 2007.
31. O'Toole JM, Rabenau KE, Burns K, et al: Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member. Cancer Res 66: 9162-9170, 2006.
32. Zhang Y, Kaplan-Lefko PJ, Rex K, et al: Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo. Cancer Res 68: 6680-6687, 2008.
33. Christensen JG, Schreck R, Burrows J, et al: A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63: 7345-7355, 2003.
34. Yao HP, Luo YL, Feng L, Cheng LF, Lu Y, Li W and Wang MH: Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase. Cancer Biol Ther 5: 1179-1186, 2006.
35. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P and Comoglio PM: Cross-talk between the proto-oncogenes Met and Ron. Oncogene 19: 3041-3049, 2000.
36. Peace BE, Hill KJ, Degen SJ and Waltz SE: Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp Cell Res 289: 317-325, 2003.
37. Torgersen ML, Skretting G, van Deurs B and Sandvig K: Internalization of cholera toxin by different endocytic mechanisms. J Cell Science 114: 3737-3747, 2001.
38. Petrelli A, Circosta P, Granziero L, Mazzone M, Pisacane A, Fenoglio S, Comoglio PM and Giordano S: Ab-induced ecto-domain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc Natl Acad Sci USA 103: 5090-5095, 2006.
39. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6: 303-313, 1999.
40. Danilkovitch-Miagkova A, Miagkov A, Skeel A, Nakaigawa N, Zbar B and Leonard EJ: Oncogenic mutants of RON and MET receptor tyrosine kinases cause activation of the beta-catenin pathway. Mol Cell Biol 21: 5857-5868, 2001.
41. Xu XM, Zhou YQ and Wang MH: Mechanisms of cytoplasmic (beta)-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem 280: 25087-25094, 2005.
42. Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 22: 186-197, 2003.
43. Dussault I, Bellon SF. From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. Anticancer Agents Med Chem 9: 221-229, 2009.
44. Thangasamy A, Rogge J and Ammanamanchi S: Recepteur d'origine nantais tyrosine kinase is a direct target of hypoxia-inducible factor-1alpha-mediated invasion of breast carcinoma cells. J Biol Chem 284: 14001-14010, 2009.
45. Zalcenstein A, Weisz L, Stambolsky P, Bar J, Rotter V and Oren M: Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53. Oncogene 25: 359-69, 2006.
46. Germano S, Barberis D, Santoro MM, Penengo L, Citri A, Yarden Y and Gaudino G: Geldanamycins trigger a novel Ron degradative pathway, hampering oncogenic signaling. J Biol Chem 281: 21710-21719, 2006.
47. Penengo L, Rubin C, Yarden Y and Gaudino G: c-Cbl is a critical modulator of the Ron tyrosine kinase receptor. Oncogene 22: 3669-3679, 2006.
48. Wang MH, Julian FM, Breathnach R, et al: Macrophage stimulating protein (MSP) binds to its receptor via the MSP beta chain. J Biol Chem 272: 16999-7004, 1997.
49. Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 357: 39-51, 2007. (Pubitemid 47026733)